330 related articles for article (PubMed ID: 23238589)
1. Re-emergence of interferon-α in the treatment of chronic myeloid leukemia.
Talpaz M; Hehlmann R; Quintás-Cardama A; Mercer J; Cortes J
Leukemia; 2013 Apr; 27(4):803-12. PubMed ID: 23238589
[TBL] [Abstract][Full Text] [Related]
2. The interferon-alpha revival in CML.
Talpaz M; Mercer J; Hehlmann R
Ann Hematol; 2015 Apr; 94 Suppl 2():S195-207. PubMed ID: 25814086
[TBL] [Abstract][Full Text] [Related]
3. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
4. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
5. Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era.
Malagola M; Breccia M; Skert C; Cancelli V; Soverini S; Iacobucci I; Cattina F; Liberati AM; Tiribelli M; Annunziata M; Trabacchi E; De Vivo A; Castagnetti F; Martinelli G; Fogli M; Stagno F; Pica G; Iurlo A; Pregno P; Abruzzese E; Pardini S; Bocchia M; Russo S; Pierri I; Lunghi M; Barulli S; Merante S; Mandelli F; Alimena G; Rosti G; Baccarani M; Russo D
Am J Hematol; 2014 Feb; 89(2):119-24. PubMed ID: 24122886
[TBL] [Abstract][Full Text] [Related]
6. Spotlight on imatinib mesylate in chronic myeloid leukemia.
Curran MP; Croom KF; Goa KL
BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
[TBL] [Abstract][Full Text] [Related]
7. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
8. Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha.
El Eit RM; Iskandarani AN; Saliba JL; Jabbour MN; Mahfouz RA; Bitar NM; Ayoubi HR; Zaatari GS; Mahon FX; De Thé HB; Bazarbachi AA; Nasr RR
Int J Cancer; 2014 Feb; 134(4):988-96. PubMed ID: 23934954
[TBL] [Abstract][Full Text] [Related]
9. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment.
Chu S; McDonald T; Lin A; Chakraborty S; Huang Q; Snyder DS; Bhatia R
Blood; 2011 Nov; 118(20):5565-72. PubMed ID: 21931114
[TBL] [Abstract][Full Text] [Related]
10. Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor.
Bhattacharya S; Zheng H; Tzimas C; Carroll M; Baker DP; Fuchs SY
Blood; 2011 Oct; 118(15):4179-87. PubMed ID: 21821707
[TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia.
Burchert A; Wölfl S; Schmidt M; Brendel C; Denecke B; Cai D; Odyvanova L; Lahaye T; Müller MC; Berg T; Gschaidmeier H; Wittig B; Hehlmann R; Hochhaus A; Neubauer A
Blood; 2003 Jan; 101(1):259-64. PubMed ID: 12393722
[TBL] [Abstract][Full Text] [Related]
12. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
[TBL] [Abstract][Full Text] [Related]
13. Chronic myeloid leukemia: standard treatment options.
Frame D
Am J Health Syst Pharm; 2006 Dec; 63(23 Suppl 8):S10-4; quiz S21-2. PubMed ID: 17106015
[TBL] [Abstract][Full Text] [Related]
14. A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)-AGMT_CML 1.
Heibl S; Buxhofer-Ausch V; Schmidt S; Webersinke G; Lion T; Piringer G; Kuehr T; Wolf D; Melchardt T; Greil R; Thaler J
Hematol Oncol; 2020 Dec; 38(5):792-798. PubMed ID: 32757230
[TBL] [Abstract][Full Text] [Related]
15. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
Liu JH; Liu CC; Yen CC; Gau JP; Wang WS; Tzeng CH
Int J Cancer; 2009 Jul; 125(1):71-7. PubMed ID: 19291793
[TBL] [Abstract][Full Text] [Related]
16. Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors.
Angstreich GR; Matsui W; Huff CA; Vala MS; Barber J; Hawkins AL; Griffin CA; Smith BD; Jones RJ
Br J Haematol; 2005 Aug; 130(3):373-81. PubMed ID: 16042686
[TBL] [Abstract][Full Text] [Related]
17. The role of interferon-alpha in the treatment of chronic myeloid leukemia.
Kujawski LA; Talpaz M
Cytokine Growth Factor Rev; 2007; 18(5-6):459-71. PubMed ID: 17703986
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase inhibitors and interferon-α increase tunneling nanotube (TNT) formation and cell adhesion in chronic myeloid leukemia (CML) cell lines.
Omsland M; Andresen V; Gullaksen SE; Ayuda-Durán P; Popa M; Hovland R; Brendehaug A; Enserink J; McCormack E; Gjertsen BT
FASEB J; 2020 Mar; 34(3):3773-3791. PubMed ID: 31945226
[TBL] [Abstract][Full Text] [Related]
19. Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells.
Parmar S; Smith J; Sassano A; Uddin S; Katsoulidis E; Majchrzak B; Kambhampati S; Eklund EA; Tallman MS; Fish EN; Platanias LC
Blood; 2005 Oct; 106(7):2436-43. PubMed ID: 15790787
[TBL] [Abstract][Full Text] [Related]
20. Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia.
Sacchi S; Kantarjian HM; Smith TL; O'Brien S; Pierce S; Kornblau S; Beran M; Keating MJ; Talpaz M
J Clin Oncol; 1998 Mar; 16(3):882-9. PubMed ID: 9508169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
